Evidence map›Paper›PMID 31616008›Full record

ArticleScientific reports2019

Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium.

Jose M Sánchez-Maldonado, Rafael Cáliz, Luz Canet, Rob Ter Horst, Olivier Bakker, Alfons A den Broeder, Manuel Martínez-Bueno, Helena Canhão, Ana Rodríguez-Ramos, Carmen B Lupiañez and 16 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 10 institutions in 4 countries.

Jose M Sánchez-MaldonadoGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
Rafael CálizGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
Luz CanetGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
Rob Ter HorstDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-0576-5873
Olivier BakkerDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Alfons A den BroederDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Manuel Martínez-BuenoArea of Genomic Medicine, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain.
Helena CanhãoCEDOC, EpiDoC Unit, NOVA Medical School and National School of Public Health, Universidade Nova de Lisboa, Lisbon, Portugal.
Ana Rodríguez-RamosGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.ORCID http://orcid.org/0000-0003-3422-2886
Carmen B LupiañezGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
María José Soto-PinoRheumatology department, Virgen de las Nieves University Hospital, Granada, Spain.
Antonio GarcíaRheumatology department, Virgen de las Nieves University Hospital, Granada, Spain.
Eva Pérez-PampinRheumatology Unit, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
Alfonso González-UtrillaRheumatology department, Virgen de las Nieves University Hospital, Granada, Spain.
Alejandro EscuderoRheumatology department, Reina Sofía Hospital/IMIBIC/University of Córdoba, Córdoba, Spain.
Juana Segura-CatenaGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
Romana T Netea-MaierDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Miguel Ángel FerrerRheumatology department, Virgen de las Nieves University Hospital, Granada, Spain.
Eduardo Collantes-EstevezRheumatology department, Reina Sofía Hospital/IMIBIC/University of Córdoba, Córdoba, Spain.
Miguel Ángel López NevotImmunology department, Virgen de las Nieves University Hospital, Granada, Spain.
Yang LiDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Manuel JuradoGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
João E FonsecaRheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, CHLN, Lisbon, Portugal.
Mihai G NeteaDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-2421-6052
Marieke J H CoenenDepartment of Human Genetics, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Juan SainzGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain. juan.sainz@genyo.es.ORCID http://orcid.org/0000-0002-9355-2423
Hospital Universitario Virgen de las Nieves · ESPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESInstituto de Investigación Biosanitaria de Granada · ESRadboud University Nijmegen · NLInstituto Maimónides de Investigación Biomédica de Córdoba · ESUniversity Medical Center Groningen · NLUniversidade de Santiago de Compostela · ESUniversidade Nova de Lisboa · PTUniversity of Bonn · DEUniversity of Lisbon · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we assessed whether 41 SNPs within steroid hormone genes associated with erosive disease. The most relevant finding was the rheumatoid factor (RF)-specific effect of the CYP1B1, CYP2C9, ESR2, FcγR3A, and SHBG SNPs to modulate the risk of bone erosions (P = 0.004, 0.0007, 0.0002, 0.013 and 0.015) that was confirmed through meta-analysis of our data with those from the DREAM registry (P = 0.000081, 0.0022, 0.00074, 0.0067 and 0.0087, respectively). Mechanistically, we also found a gender-specific correlation of the CYP2C9

Indexed as

AdultAgedArthritis, RheumatoidBone DiseasesCytochrome P-450 CYP1B1Cytochrome P-450 CYP2C9Disease ProgressionFemaleGonadal Steroid HormonesHaplotypesHumansMaleMiddle AgedPolymorphism, Single NucleotidePredictive Value of TestsPrognosisCYP1B1 protein, humanCYP2C9 protein, humanCytochrome P-450 CYP1B1Cytochrome P-450 CYP2C9Gonadal Steroid HormonesRheumatoid Factor

Identifiers

PMID31616008
PMCPMC6794376
OpenAlexW2980890691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.